Please login to the form below

Not currently logged in
Email:
Password:

MSD invests in FKD Therapies

MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker

MSD (known as Merck in the US and Canada) has taken an equity stake in the Finland based company, FKD Therapies. FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark Therapeutics.

This investment by MSD constitutes part of a deal that will see FKD Therapies develop MSD's gene therapy portfolio, which includes a possible treatment for bladder cancer.

The possible bladder treatment that FKD Therapies will be developing contains an adenovirus, which is designed to carry an interferon gene into the bladder wall cells. Here, it expresses a protein within the bladder, possibly increasing its ability to penetrate tumour cells.

MSD's gene therapy programmes for glaucoma surgery failure and the treatment of solid tumours were also available to develop.

20th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics